Daniel C. Christoph
Herne, NW 44651, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
Predictive Factors for Mediastinal Lymph Node Metastases in Patients with Non-small Cell Lung Cancer, as Detected by Video-assisted Mediastinoscopic Lymphadenectomy.
Journal: Zentralblatt fur Chirurgie
Published: June 16, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.
Journal: Clinical lung cancer
Published: March 26, 2026
Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany.
Journal: Therapeutic advances in medical oncology
Published: November 07, 2025
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.
Journal: Clinical and translational radiation oncology
Published: October 21, 2025
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.
Journal: ESMO open
Published: September 11, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 29, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 13, 2025
CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.
Journal: Oncology research and treatment
Published: August 30, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 29, 2024
Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis.
Journal: Oncology
Published: February 04, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Journal: ESMO open
Published: November 23, 2023
Last Updated: 09/26/2026